All In Biotech

Drug Trial Radar · NCT05259917

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II

Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Feb 22, 2022

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients

Conditions

  • Hereditary Angioedema

Interventions

  • PlaceboDrug

    Placebo to KVD900 Tablet

  • KVD900 600 mgDrug

    KVD900 Tablet 600 mg (2 x 300 mg)

  • KVD900 300 mgDrug

    KVD900 Tablet 300 mg (1 x 300 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C)Time frame: Within 12 hours of the first investigational medicinal product (IMP) administration.

Locations

66 sites in 21 countries. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Birmingham, Alabama

  • KalVista Investigative Site

    Scottsdale, Arizona

  • KalVista Investigative Site

    Little Rock, Arkansas

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    Santa Monica, California

  • KalVista Investigative Site

    Centennial, Colorado

  • KalVista Investigative Site

    Colorado Springs, Colorado

  • KalVista Investigative Site

    Tampa, Florida

  • KalVista Investigative Site

    Chicago, Illinois

  • KalVista Investigative Site

    Overland Park, Kansas

  • KalVista Investigative Site

    Louisville, Kentucky

  • KalVista Investigative Site

    Chevy Chase, Maryland

  • KalVista Investigative Site

    Plymouth, Minnesota

  • KalVista Investigative Site

    St Louis, Missouri

  • KalVista Investigative Site

    New York, New York

  • KalVista Investigative Site

    Charlotte, North Carolina

  • KalVista Investigative Site

    Toledo, Ohio

  • KalVista Investigative Site

    Hershey, Pennsylvania

  • KalVista Investigative Site

    Dallas, Texas

  • KalVista Investigative Site

    Layton, Utah

  • KalVista Investigative Site

    Spokane, Washington

  • KalVista Investigative Site

    Campbelltown, New South Wales, Australia

  • KalVista Investigative Site

    Sofia, Bulgaria

  • KalVista Investigative Site

    Toronto, Ontario, Canada

  • KalVista Investigative Site

    Grenoble, France

  • KalVista Investigative Site

    Lille, France

  • KalVista Investigative Site

    Lille, France

  • KalVista Investigative Site

    Paris, France

  • KalVista Investigative Site

    Berlin, Germany

  • KalVista Investigative Site

    Mainz, Germany

  • KalVista Investigative Site

    Mörfelden-Walldorf, Germany

  • KalVista Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Kalvista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Budapest, Hungary

  • KalVista Investigative Site

    Haifa, Israel

  • KalVista Investigative Site

    Petach Tikvah, Israel

  • KalVista Investigative Site

    Ramat Gan, Israel

  • KalVista Investigative Site

    Tel Aviv, Israel

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.